Please assess the completion status of the following clinical trial:

Trial Title: A Study Evaluating if Pridopidine is Safe, Efficacious, and Tolerable in Patients With Huntington's Disease

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Pride HD completion within the last 6 months, including 2 week follow up period or patients who transitioned from the Open HART study or patients who complete future safety and efficacy clinical trials of pridopidine. In addition, patients who have already completed their defined study period under Open PRIDE HD global or local amendments and have discontinued treatment with pridopidine will be allowed to re enter the Open PRIDE HD study.~* Women of child bearing potential or male participants: Adequate contraception and birth control~* Good general health~  * other criteria apply, please contact the investigator for more information~Exclusion Criteria:~* Similar baseline criteria for ECG, vital signs, cardiovascular system, and renal function to PRIDE HD;~* Similar concomitant medication restrictions to PRIDE HD.~  * other criteria apply, please contact the investigator for more information

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Pridopidine (Type: EXPERIMENTAL): The mode of administration is oral. Capsules will be swallowed whole with water. One capsule should be taken in the morning and 1 in the afternoon, 7 to 10 hours after the morning dose. Study drug can be taken irrespective of meals.

Based on this trial design, predict the completion outcome and termination type (if applicable).